Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.72 |
| ▸ | DRD3 | P35462 | 11/20 | 0.72 |
| ▸ | HTR2A | P28223 | 9/20 | 0.72 |
| ▸ | DRD2 | P14416 | 8/20 | 0.72 |
| ▸ | HTR1A | P08908 | 8/20 | 0.72 |
| ▸ | HTR2C | P28335 | 4/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | HRH1 | P35367 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9631705 | 0.84 | HTR1A (0.66) | SLC6A4DRD3HTR2ADRD2HTR1A | |
| SCHEMBL4526369 | 0.82 | DRD3 (1.00) | SLC6A4DRD3HTR2ADRD2HTR1A | |
| SCHEMBL13711966 | 0.82 | DRD3 (1.00) | SLC6A4DRD3HTR2ADRD2HTR1A | |
| SCHEMBL4519092 | 0.81 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| SCHEMBL14761668 | 0.81 | HTR1A (0.70) | SLC6A4DRD3HTR2ADRD2HTR1A | |
| SCHEMBL4521349 | 0.81 | DRD3 (0.73) | DRD3HTR2ADRD2HTR1AHTR2C | |
| SCHEMBL7053717 | 0.80 | DRD3 (0.71) | SLC6A4DRD3HTR2ADRD2HTR1A | |
| SCHEMBL1039928 | 0.80 | DRD3 (1.00) | SLC6A4DRD3HTR2ADRD2HTR1A | |
| SCHEMBL28071107 | 0.78 | PLD1 (0.62) | DRD3HTR2ADRD2HTR1AHTR2C | |
| SCHEMBL7058620 | 0.78 | DRD2 (0.69) | SLC6A4DRD3HTR2ADRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | claimed |
| EP-1836192-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Universita' Degli Studi di Siena (IT) | 2007-09-26 | — | — | EP | claimed |
| WO-2006072608-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2006-07-13 | — | — | WO | claimed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| EP-1836192-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Universita' Degli Studi di Siena (IT) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072608-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | SLC6A4 27/4885DRD3 10/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.